The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache
The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache
To develop a pragmatic migraine model the investigators will induce headache in patients with
 migraine without aura with a phosphodiesterase inhibitor (cilostazol). If the headache
 responds to sumatriptan injection, the model can be used to test new drug candidates.
There remains a great need for more effective anti-migraine drugs with fewer side effects.
 Human experimental models are valuable in early phase development of new anti-migraine drugs
 but useful models have not yet been developed. The investigators' group has shown that
 Cilostazol, a phosphodiesterase inhibitor induce headache/migraine in both healthy volunteers
 and in patients with migraine without aura (MO). To validate this model, the headache must
 respond to specific migraine treatment with sumatriptan.

 Hypothesis: Cilostazol induces a migraine-like headache in MO-patients and the induced
 headache responds to sumatriptan injection Aim: Developing a pragmatic and valid model for
 the testing of new anti-migraine drugs.
Inclusion Criteria:

 -  Migraine patients who meet IHS criteria for migraine with or without aura of both
 sexes

 -  18-70 years

 -  45-95 kg.

 Exclusion Criteria:

 -  Any other type of headache then migraine without aura (except episodic tension-type
 headache < 1 day per week)

 -  Serious somatic or psychiatric disease

 -  Pregnancy

 -  Intake of daily medication (except oral contraceptives)

 -  Triptan non-responders